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A B S T R A C T
The maintenance of the characteristic lipid compositions and physicochemical properties of biological mem-
branes is essential for their proper function. Mechanisms allowing to sense and restore membrane homeostasis
have been identiﬁed in prokaryotes for a long time and more recently in eukaryotes. A membrane remodeling
can result from aberrant metabolism as seen in obesity. In this review, we describe how such lipid bilayer stress
can account for the modulation of membrane proteins involved in the pathogenesis of obesity-linked in-
ﬂammatory and metabolic disorders. We address the case of the Toll-like receptor 4 that is implicated in the
obesity-related low grade inﬂammation and insulin resistance. The lipid raft-mediated TLR4 activation is pro-
moted by an enrichment of the plasma membrane with saturated lipids or cholesterol increasing the lipid phase
order. We discuss of the plasma membrane Na, K-ATPase that illustrates a new concept according to which direct
interactions between speciﬁc residues and particular lipids determine both stability and activity of the pump in
parallel with indirect eﬀects of the lipid bilayer. The closely related sarco(endo)-plasmic Ca-ATPase embedded in
the more ﬂuid ER membrane seems to be more sensitive to a lipid bilayer stress as demonstrated by its in-
activation in cholesterol-loaded macrophages or its inhibition mediated by an increased PtdCho/PtdEtn ratio in
obese mice hepatocytes. Finally, we describe the model recently proposed for the activation of the conserved
IRE-1 protein through alterations in the ER membrane lipid packing and thickness. Such IRE-1 activation could
occur in response to abnormal lipid synthesis and membrane remodeling as observed in hepatocytes exposed to
excess nutrients. Since the IRE-1/XBP1 branch also stimulates the lipid synthesis, this pathway could create a
vicious cycle “lipogenesis-ER lipid bilayer stress-lipogenesis” amplifying hepatic ER pathology and the obesity-
linked systemic metabolic defects.
Cellular membranes are highly organized structures mainly com-
posed of lipids. Diﬀerent types of proteins facilitating cellular functions
and adaptation to stress are also found into lipid membranes, including
both integral and peripheral membrane proteins. The original ﬂuid
mosaic model of biological membranes was introduced 40 years ago by
Singer and Nicolson describing some globular integral membrane pro-
teins and glycoproteins free to diﬀuse laterally in the ﬂuid lipid mem-
brane plane [1]. This model is still currently applicable for most ex-
perimental conditions but additional informations such as protein and
lipid aggregations into domains, cytoskeleton and extracellular matrix
interactions are now part of a deeper view of membrane regulation and
hierarchy. Besides heterogeneity of membrane domains, forces that
dictate membrane curvature, deformation and expansion add com-
plexity to the dynamic of lipidic structures in constant remodeling to
assume their biological functions. The amphiphilic properties of lipids
permit them to self-assemble creating micelles or bilayers. Water forms
a hydrogen bond cage on the surface of the hydrophilic head groups of
lipids while their hydrophobic tails are protected [2]. This property not
only allows cells to create a wall between internal constituents and
external environment, but also to delineate internal compartments and
restricted places where chemical reactions are taking place to increase
biochemical eﬃciency [3].
Biological membranes are functionalized by the embedding of
membrane proteins that act as receptors, transporters, channels, en-
zymes and structural elements. Many crucial signaling processes occur
at membrane surfaces. Moreover, a speciﬁc membrane composition
confers a proper function on each organelle. Therefore, cells are
equipped with surveillance systems to maintain membrane home-
ostasis. Lipids have key roles in membrane remodeling processes.
Accordingly, their biosynthesis has to be tightly regulated.
In this review, we will start by describing the structure, the physi-
cochemical properties and the synthesis pathways of the main struc-
tural lipids of eukaryotic membranes. This ﬁrst part will allow a better
understanding of both the mechanisms and consequences of membrane
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remodeling that occurs in some circumstances like in obesity-related
metabolic disorders. In the second part, we will focus on some mem-
brane proteins whose function is modulated by lipid bilayer modiﬁca-
tions. Finally, we will review mechanisms developed in prokaryotes and
eucaryotes to sense and restore membrane ﬂuidity. We will put the
emphasis on the underlying physicochemical mechanisms and on the
relevance in obesity-linked inﬂammatory and metabolic disorders.
1. Membrane composition and structure
1.1. Membrane lipids
1.1.1. Glycerophospholipids
The glycerophospholipids are the building blocks of cellular mem-
branes. They are characterized by an amphipathic structure with a
hydrophobic tail composed of two fatty acyl chains ester bond-linked to
positions 1 and 2 (sn-1 and -2) of a glycerol backbone and a hydrophilic
head group consisting of a phosphate group linked to position 3 (sn-3)
of the glycerol with a phosphodiester bond (Fig. 1A) [4]. The phos-
phatidic acid (PA) is the most basic structure and an important inter-
mediate in the synthesis of glycerophospholipids that carry an addi-
tional group attached to the phosphate. According to the nature of this
head group, glycerophospholipids can be divided into four classes:
phosphatidylcholine (PtdCho), phosphatidylethanolamine (PtdEtn),
phosphatidylinositol (PtdIns), phosphatidylserine (PtdSer) (Fig. 1A).
Variations in head groups and aliphatic chains of lipids permit the
eukaryotic cell to reach more than 1000 diﬀerent lipid species with only
5% of the cell genes involved [5]. The head group of PtdCho and PtdEtn
is zwitterionic while the one of PtdIns and PtdSer is anionic. In mam-
malian cells, the PtdCho reach up to 55% of total lipids while PtdEtn,
PtdIns and PtdSer count for 15–25%, 10–15% and 5–10%, respectively
[6].
PtdCho’s cylindrical molecular geometry permits them to self-as-
semble automatically into bilayers (Fig. 1B). The PtdEtn conical shape
imposes curvature stresses on the membrane (Fig. 1B) [7,8]. The non-
bilayer propensity of PtdEtn eases the membrane fusion and binding of
peripheral membrane proteins [7,8]. Anionic lipids such as PtdSer and
PtdIns are implicated in membrane charge and facilitate the interac-
tions with positively charged domains of peripheral and integral
membrane proteins [9,10]. The term “lyso” refers to the glycerolipids/
glycerophospholipids carrying only one acyl chain. They have a large
hydrophilic head group compared to their hydrophobic tail. These li-
pids tend to pack in highly curved structures (Fig. 1B) [11]. In addition
to lysophosphatidic acid (LPA), lysophosphatidylcholine (LPC) is the
major lysophospholipid.
Hydrophobic chains of membrane glycerophospholipids are com-
monly divided in two subclasses according to whether they are derived
from saturated fatty acids (SFAs) characterized by a straight hydro-
carbon chain containing most often an even number of carbon atoms or
from monounsaturated (MUFA) or polyunsaturated fatty acids (PUFA)
containing one or several double bonds, respectively, making the hy-
drocarbon chain bent (Fig. 1A) [12,13]. The acyl moieties attached to
sn-2 of glycerophospholipid’s glycerol backbone are commonly un-
saturated, unlike the sn-1 moieties that are usually saturated (Fig. 1A)
[4]. Aliphatic chains derived from FAs usually contain 12 to 22 carbon
atoms [14]. The physicochemical properties of FAs and FAs-derived
lipids depend on both the chain length and the saturation level of the
acyl chains. UFAs exhibiting a cis-conﬁguration, as referred in this re-
view, have lower melting points than SFAs of the same length [15].
Fig. 1. Membrane lipids. Chemical structures (A) and geometrical shapes (B) of (lyso)glycerophospholipids, chemical structures of sphingolipids (C) and cholesterol (D). PA, phosphatidic
acid, LPA, lysophosphatidic acid, LPC, lysophosphatidylcholine, PtdCho, phosphatidylcholine, PtdEtn, phosphatidylethanolamine, PtdSer, phosphatidylserine and PtdIns, phosphati-
dylinositol.
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1.1.2. Sphingolipids and sterols
Besides glycerophospholipids, another structural lipid class is re-
presented by sphingolipids. Ceramide contains a long-chain sphingo-
sine base amide-linked to a saturated or trans-unsaturated FA chain
(Fig. 1C). This backbone can be linked with phosphocholine or phos-
phoethanolamine to give rise to sphingomyelin, or with saccharides in
the case of glycosphingolipids. Shingomyelin (SM), due to its narrow
cylinder shape, increases the packing density in the membrane [6,16].
In mammals, sterols are represented by cholesterol. The structure of
sterols consists in four fused rings forming the steroid nucleus: three
rings containing six carbons and one ring with ﬁve carbons. Cholesterol
is composed of the steroid nucleus, a polar hydroxyl group and a hy-
drocarbon tail (Fig. 1D) [4]. Cholesterol creates a condensing eﬀect,
increasing membrane thickness and impermeability to solutes by in-
terfering with neighboring unsaturated acyl chains and by immobilizing
them and reducing their ﬂexibility. Besides, due to its inﬂexible core
formed by the steroid nucleus, cholesterol interferes with acyl chains
packing in the membrane. This property allows cholesterol to maintain
the membrane ﬂuid in a large temperature range independently of the
composition of membrane acyl chains. It is also important in the for-
mation of membrane domains with sphingomyelin due to their property
to form 1:1 dimers [9,17,18].
1.2. Membrane properties
The membrane lipid composition of each organelle varies according
to their specialized tasks. Endoplasmic reticulum (ER) is the organite
mediating both the protein folding and lipid synthesis [19]. It is the
main site where membrane proteins are inserted [19]. The lipid com-
position of ER and plasma membranes is deﬁnitively diﬀerent. Adapted
to its barrier function, the plasma membrane is thick and tightly packed
with a negative cytoplasmic surface charge, unlike the ER membrane
that is composed of a thin lipid bilayer with loose packing and a neutral
cytoplasmic charge [9]. Their speciﬁcity is also governed by diﬀerences
in the length and shape of transmembrane domains (TMDs) of their
proteins. PtdCho, PtdEtn, SM, PtdIns, and PtdSer approximatively re-
present 43%, 21%, 23%, 7% and 4% of the rat liver plasma membrane
phospholipids, respectively, with a cholesterol/phospholipid ratio of
0,76 [6]. The concentration in saturated lipid species, beside sterols and
sphingolipids (10–20% and 5–10% of total lipids, respectively) is high
in the plasma membrane making it rigid and thick to protect cells from
external aggressions. However, the PtdCho, PtdEtn, SM, PtdIns, and
PtdSer approximatively represent 57%, 21%, 4%, 9% and 4% of rat
liver ER membrane phospholipids, respectively, with a very low cho-
lesterol/phospholipid ratio of 0,07 [6]. Sterols and sphingolipids are
low in the ER while this organelle is the primary site of their bio-
synthesis. ER supplies ceramide to trans-Golgi to form sphingolipids
[9,20,21]. Actually, the transition from the thin and loose ER/cis-Golgi
membranes into the thick plasma membrane occurs in the trans-Golgi
due to its sphingolipid production and sterol supply [22]. Golgi is
therefore divided into two distinct parts, cis-Golgi and trans-Golgi, each
characterized by a speciﬁc membrane composition and organization.
Mitochondria possess bacterial lipids and around 45% of its phos-
pholipids are autonomously synthesized by the organelle. Phosphatidic
acid (PA) and phosphatidylglycerol (PtdGro) are synthesized by mi-
tochondria and used as building blocks for an unique mitochondrial
lipid called cardiolipin (CL) (2–5% of total lipids) [6,23]. As PtdEtn,
mitochondrial CL also acquires a preference for non-bilayer conﬁg-
uration [21]. Moreover the mitochondria decarboxylate the PtdSer to
produce PtdEtn. PtdEtn is thus particularly enriched in inner mem-
branes of mitochondria (35–40% of total phospholipids) [6]. In general,
the sterol content is low, except for specialized cells in steroid hormone
synthesis [24].
Lipid droplets (LD) are the lipid storage organelle found in all living
organisms. Besides the neutral lipids triacylglycerol (TG) and dia-
cylglycerol (DG), the LD core can also contain sterol esters and
depending on the cell type, retinyl esters, waxes and ether lipids
[25,26]. The composition of the LD phospholipid monolayer depends
on the cell type, but mainly consists of PtdCho, PtdEtn, and to a lesser
extent, PtdIns and lysophospholipids.
1.2.1. Membrane ﬂuidity
Fluidity is deﬁned as “the quality of a substance of being not solid
and able to ﬂow” [27]. According to the ﬂuid mosaic model, a biolo-
gical membrane is a two-dimensional ﬂuid allowing lipids and proteins
to diﬀuse freely in the plane of the membrane [1]. The current model
also takes into account protein complexes, protein-lipid and lipid-lipid
interactions. The “ﬂuid” character of a membrane depends on its
composition. A disordered, ﬂuid state is imparted by the presence of
unsaturated acyl chains that act to oﬀset the closely packed, ordered
arrangement of the straight, saturated acyl chains. Multiple possible
phase states co-exist in the plasma membrane due to its varied lipid
composition. The packed ordered phase enriched in saturated lipids is
called the liquid-ordered (Lo) phase. The ﬂuid and disordered phase is
mainly composed of unsaturated lipids with a kinked shape and is
called the liquid-disordered (Ld) phase [28,29]. The presence of cho-
lesterol restricts the movement of surrounding acyl chains but main-
tains ﬂuidity of the bilayer, inducing a so-called liquid-ordered phase.
Long saturated hydrocarbon chains like in SM-rich mixture of lipids
adopt a solid-like phase (So). Both acyl chain length and saturation level
aﬀect the membrane phase. However, in most biological membranes
composed of glycerophospholipids with unsaturated hydrocarbon
chains, liquid-phases are predominant. In fact, artiﬁcial mixtures of li-
pids containing di-saturated PtdCho, di-unsaturated PtdCho and cho-
lesterol are completely miscible like a liquid disordered lipid bilayer at
physiological temperature. This miscibility is allowed by the un-
saturated hydrocarbon chains of glycerophospholipids and deﬁnes the
ﬂuid state of biological membranes with a coexistence of Lo and Ld
phases [23,30].
Membrane ﬂuidity can be described and measured by diverse
spectroscopic methods, but less demanding techniques, such as micro-
scopy with ﬂuorescent probes, are more frequently used. Designed and
synthesized by Gregorio Weber, the Laurdan is a polarity-sensitive
ﬂuorescent probe [31]. When inserted into lipid membrane, Laurdan
distributes equally between the Lo and Ld phases but shows a phase-
dependent emission spectrum. This property gives it a great advantage
over other probes that show a non homogenous partitionning in
membranes and are insensitive to lipid phase states (such as 1,6-di-
phenyl-1,3,5-hexatriene, pyrene and parinaric acid). More the lipids are
tightly packed in ordered phases, more water is eﬃciently excluded and
more the ﬂuorescence spectrum of Laurdan shifts from the green
(490 nm) to the blue (440 nm) [32–34].
1.2.2. Membrane rafts
In 2006, a Keystone symposium gave rise to a consensus deﬁnition
of the membrane rafts: “Membrane rafts are small (10–200 nm), het-
erogeneous, highly dynamic, sterol- and sphingolipid-enriched domains
that compartmentalize cellular processes”. Small rafts can sometimes be
stabilized to form larger platforms through protein-protein and protein-
lipid interactions [35]. The preferential interaction between sphingo-
lipids and cholesterol through strong hydrogen bonds is the principal
characteristic of these ordered lipid domains [36]. Saturated glycer-
ophospholipids are also major components of these domains besides
ganglioside lipids, a class of glycosphingolipids capable of interacting
with cholesterol enriched domains [37]. Post-translationally modiﬁed
cell surface proteins that carry either the glycosylphosphatidylinositol
(GPI) moiety as a membrane anchor or palmitoyl moieties usually favor
the lipid raft formation [38]. These lipid-anchored proteins are believed
to regulate membrane structure and function. Proteins incorporated
into these ordered domains seem to represent 35% of all plasma
membrane proteins but only one-third among them are GPI-anchored or
palmitoylated [39]. The proteins embedded in such thicker and more
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ordered domains of the plasma membrane are characterized by longer
transmembrane domains [40]. Cortical actin cytoskeleton inﬂuences
the membrane organization and stabilizes membrane rafts through its
direct or indirect coupling with charged and saturated acyl-chain-con-
taining lipid species such as PtdSer [41,42]. In presence of cholesterol,
this phenomenon orchestrates the immobilization of inner leaﬂet
PtdSer that are engaged in transbilayer interactions with long acyl
chain–containing GPI-anchored proteins located in the outer leaﬂet. All
these interactions between lipids and proteins lead to the formation of
locally ordered transbilayer domains [41,42].
Membrane rafts compartmentalize cellular signaling in the plasma
membrane. In fact, these domains facilitate the concentration of certain
proteins in one speciﬁc region of the plasma membrane according to
their aﬃnity for rafts components. Moreover, rafts composition can
aﬀect protein conformation and thereby regulate protein activity
[43,44]. Immunoreceptors like high aﬃnity IgE receptor, T cell re-
ceptor (TCR) and B cell receptor (BCR) translocate to membrane rafts
following their activation [45,46].
2. Lipid synthesis and remodeling
2.1. De novo lipogenesis
De novo FA synthesis or de novo lipogenesis (DNL) is the metabolic
pathway that transforms excess of carbohydrate in FAs (Fig. 2) [47].
FAs are composed of a hydrocarbon chain with a methyl group at one
end of the molecule (designated ω end) and a carboxyl group at the
other end. The letter “ω” is often used to describe the position of the
double bond closest to the methyl end. Another systematic nomen-
clature for fatty acids may also indicate the location of double bonds
with reference to the carboxyl group (Δ) [15]. FAs can also be desig-
nated as X:Y, where X is the number of carbon atoms and Y the number
of double bonds (e.g. C16:0 for palmitic acid and C18:1 for oleic acid)
[15].
In normal conditions, DNL mainly takes place in adipose tissue and
liver even if adipose tissue is less responsive to acute or prolonged
carbohydrate overfeeding [48]. Fatty acid synthesis occurs in the cy-
tosol (Fig. 2). A citrate molecule, issued from the tricarboxylic acid
cycle (TCA) in mitochondria, is hydrolyzed by the “Adenosine
triphosphate (ATP) citrate lyase” (ACLY), which generates an acetyl-
CoA. This one is then converted into malonyl-CoA by the “acetyl-CoA
carboxylase” (ACACA or ACC). The multi-enzymatic complex, com-
monly called “fatty acid synthase” (FASN), processes an acetyl-CoA and
several malonyl-CoA to generate the palmitate (C16:0), the main pro-
duct of DNL beside stearate (C18:0) and shorter fatty acids [47]. The
glycolytic pathway supplies a carbon source for FA synthesis [49,50].
The expression of genes involved in de novo fatty acid synthesis is
tightly regulated by both the transcription factors ChREBP (carbohy-
drate responsive element-binding protein) and SREBP (sterol regulatory
element-binding protein), whose activity is respectively induced by
glucose and lipid metabolism intermediates [47,50–52].
2.2. FA elongation and desaturation
The ER contains enzymatic machinery allowing the addition of two
extra carbon units and of a double bond in the fatty acyl chain (Fig. 2).
FA elongation process is a repetition of the FA elongation cycle whereby
two carbons are added to the carboxyl end. This cycle consists in four
sequential reactions: condensation, reduction, dehydration and another
reduction [53]. The ﬁrst rate-limiting reaction is catalyzed by enzymes
that belong to ELOVL family (Elongation of very-long-chain fatty acids)
composed of seven isotypes (ELOVL1-7) [53,54]. The introduction of
cis-unsaturation at speciﬁc locations in the acyl chain is achieved by
two distinct enzyme families referred as stearoyl-CoA desaturases
(SCD1 and SCD2) and fatty acid desaturases (FADS1 and FADS2). De-
saturases inﬂuence key biological reactions and mammalian cells only
express Δ9-, Δ6- and Δ5-desaturase activities. Accordingly, long-chain
fatty acids of the ω6 and ω3 series have to be synthesized from pre-
cursors obtained from diet [53].
2.3. Lipid homeostasis: the SREBP pathway
Newly synthesized FAs will serve for energy storage when in-
corporated in TGs or will be used for membrane phospholipid synthesis.
However, overproduction of lipids can be deleterious for the cell and
toxic for the whole living organism, suggesting that regulatory me-
chanisms controlling cellular lipid levels are mandatory for cell survival
and proliferation [55]. These are mediated by a family of ER mem-
brane-bound transcription factors called sterol regulatory element-
binding proteins (SREBPs) [56]. SREBPs can sense cellular levels of FAs
or sterols and modulate transcription of genes coding for lipogenic
enzymes. The full length SREBP is sequestered in the ER membrane
through its interaction with the SREBP cleavage-activation protein
(SCAP) and the insulin-induced gene protein-1 (Insig-1) [57]. When
cellular levels of FAs or sterols are low, the SREBP/SCAP complex
dissociates from Insig-1 and is transported to the Golgi. SREBP is then
processed successively by Site-1 and Site-2 Proteases (S1P and S2P).
Once released, the NH2-terminal bHLH-Zip domain of SREBPs translo-
cates to the nucleus [58,59] where it binds enhancer sequences located
in the promoter of genes controlling lipid synthesis, called sterol re-
sponse elements (SREs) [55,60].
Three isoforms of SREBPs are produced in mammals: SREBP-1a,
SREBP-1c and SREBP-2 [61]. SREBP1a and SREBP1-c are produced by
alternate promoters from a single gene and are more active in driving
transcription of FA biosynthesis genes. SREBP-2 is produced by another
gene and is more active in controlling transcription of genes regulating
cholesterol production [60,62]. SREBP1 is subject to feedback inhibi-
tion by PUFAs because its transcription mediated by the nuclear liver X
receptors (LXRs) is antagonized by PUFAs [63–65]. In human, the LXR
response element is found in the promoter regions of both SREBP-1a
and SREBP-1c [66]. Sterols and UFAs, opposite to SFAs, also inhibit
SREBP activation but through another mechanism involving the
blocking of Insig-1 degradation [67–69].
Fig. 2. De novo lipogenesis is a coordinate serie of enzymatic reactions that use the
carbons from glucose to generate FAs. The glycolytic pathway generates pyruvate from
glucose. In the mitochondrion, pyruvate feeds the tricarboxylic acid (TCA) cycle. A TCA
intermediate, the citrate, can be translocated into the cytosol and converted into acetyl-
CoA by ATP-citrate lyase (ACYL). Acetyl-CoA is further carboxylated to malonyl-CoA by
acety-CoA carboxylase (ACACA). The multi-enzymatic complex, commonly called «fatty
acid synthase» (FASN) processes an acetyl-CoA and several malonyl-CoA to generate a
fatty acid, commonly the palmitate, a 16-carbon saturated fatty acid. This could be
elongated and de-saturated into complex fatty acids by ER enzymes.
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2.4. The glycerophosphate pathway
The synthesis of both glycerolipids (DG and TG) and glyceropho-
spholipids shares common steps and starts from glycerol-3-phosphate.
The incorporation of two fatty acyl chains is successively catalyzed by
glycerol-3-phosphate acyltransferases (GPATs) and acyl-glycerol-3-
phosphate acyltransferases (AGPATs) (Fig. 3) [70]. Four GPATs
(GPAT1, GPAT2, GPAT3/AGPAT10, and GPAT4/AGPAT6) and at least
two AGPATs (AGPAT1 and AGPAT2) are known to be involved in these
processes [70]. The speciﬁcity of GPATs/AGPATs for fatty acyl-CoA
determines the fatty acid composition of the newly synthesized glycero
(phospho)lipids [70]. PA is used as an intermediate for the synthesis of
glycerophospholipids including the PtdIns, the mitochondrial CL and
the PtdGro (Fig. 3) [6]. PA is also dephosphorylated through the lipins
(or phosphatidic acid phosphatases, PAP) to form DG that serves as
building block for the synthesis of both glycerophospholipids such as
the PtdCho, PtdEtn, PtdSer and TG (Fig. 3) [71]. A third round of
acylation is needed in order to synthesize TG from DG via the dia-
cylglycerol acyltransferases (DGAT1, DGAT2) (Fig. 3) [72]. In ER, PA
serves to build the PtdCho, both the building block of cellular mem-
branes and a potential source of lipid mediators, through the CDP
(cytidine diphosphate)-choline pathway also called Kennedy pathway
(Fig. 3) [73]. The majority of PtdEtn are synthesized via the CDP-
ethanolamine pathways while PtdIns, PtdGro and CL are synthesized
via the CDP-DG pathway (Fig. 3) [6]. An alternative PtdCho synthesis
pathway involves the conversion of PtdEtn in PtdCho by three methy-
lation reactions catalyzed by the PtdEtn N-methyltransferase (Pemt).
But the only mammalian cell type producing 30% of their total PtdCho
content by this way is hepatocyte [74].
2.5. Lipid remodeling
The acyl groups of glycerophospholipids show a high diversity and
are not symmetrically distributed. This diversity is not fully explained
by the Kennedy pathway. This pathway can explain a highly diverse
fatty acid composition generated at the sn-2 position of PA but not of
PtdCho, PtdEtn, PtdSer, PtdIns, CL and PtdGro. Saturated and mono-
unsaturated acyl groups are esteriﬁed at the sn-1 position, whereas
polyunsaturated fatty acyl groups are localized at the sn-2 position of
glycerophospholipids [75]. In 1958, Lands described a rapid turnover
of the sn-2 fatty acyl groups of glycerophospholipids as a remodeling
pathway also called the Lands cycle (Fig. 3) [76]. Besides the genera-
tion of membrane glycerophospholipids diversity, this pathway also
allows the production of lipid derivatives and lysophospholipids. This
cycle is governed by the orchestred activation of phospholipases A2s
(PLA2s) and lysophospholipid acyltransferases (LPLATs) (Fig. 3)
[77–79]. To date, LPLATs belong to the 1-acylglycerol-3-phosphate O-
acyltransferase (AGPAT) family and to the membrane bound O-acyl-
transferase (MBOAT) family [79].
2.5.1. PUFA containing-glycerophospholipids
The concerted action of PLA2s and LPLATs is an important source of
PUFA-containing glycerophospholipids [78]. Diﬀerent enzymes with
LPC acyltransferase (LPCAT) activity, including LPCAT2 and LPCAT3,
are reported to incorporate PUFAs into lysophospholipids. These en-
zymes have substrate preferences and are expressed diﬀerently [80].
For example, LPCAT2 is believed to contribute to the production of
lipid mediators in inﬂammatory cells such as macrophages and neu-
trophils where it is highly expressed [81]. Besides, the expression of
LPCAT3 is ubiquitous, controlled by PPARalpha and liver X nuclear
receptors and induced during adipogenesis [82–85]. In HeLa cells, the
Fig. 3. The glycerophosphate pathway. The two ﬁrst steps of the glycerophospholipids (GPLs) and glycerolipids synthesis are common and consist of the successive addition of two fatty
acyl chains to the glycerol-3-phosphate by the glycerol-3-phosphate acyltransferases (GPATs) and the acyl-glycerol-3-phosphate acyltransferases (AGPATs), respectively. The resulting
phosphatic acid (PA) can be used for the synthesis of phosphatidylinositol (PtdIns), phosphatidylglycerol (PtdGro) and cardiolipin (CL) through the CDP (cytidine diphosphate-choline)-
DG pathway. PA is also dephosphorylated into diacylglycerol (DG) by the lipins (or phosphatidic acid phosphatases, PAPs). The addition of a third fatty acyl chain catalyzed by the
diacylglycerol acyltransferases (DGATs) gives rise to the triacylglycerol (TG). Besides, the Kennedy and the CDP-Ethanolamine pathways allow the production of phosphatidylcholine
(PtdCho) and phosphatidylEthEtnanolamine (PtdEtn) from DG, respectively. Phosphatidylserine (PtdSer) can be generated from both PtdCho and PtdEtn. Lysophosphatidic acid (LPA) is
an intermediate in the synthesis of PA. In the remodeling pathway, also called Lands cycle, phospholipases A2s (PLA2s) can convert GPLs to lysophospholipids (LPLs) by inducing the
release of the acyl chain from sn-2 position. LPLs can be reacylated by lysophospholipid acyltransferases (LPLATs), giving rise to GPLs with a diﬀerent acyl chain at sn-2 position.
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knockdown of LPCAT3 caused reduced incorporation of PUFAs into
PtdCho, PtdEtn and PtdSer [86]. Mouse LPCAT3 shows higher acyl-
transferase activity towards polyunsaturated fatty acyl-CoAs, 20:4-CoA
and 18:2-CoA, than towards saturated fatty acyl-CoAs [79,80]. More-
over, induction of LPCAT3 ameliorates SFA-mediated ER stress in vitro,
which involves LPCAT3 in the control of inﬂammation through the
remodeling of PtdCho fatty acid composition [87]. Thus, it is obvious
that the Lands cycle brings another dimension to the lipogenesis
through the production of PUFAs and their incorporation in plasma
membranes.
3. Membrane remodeling and obesity-linked metabolic disorders
Biological membranes can undergo various kinds of modiﬁcations
which diﬀerentially impact their physico-chemical properties. This re-
modeling can aﬀect the acyl chains (length, saturation degree) or the
head groups of the glycerophospholipids as well as the incorporation of
other lipids like sterols and sphingolipids. In general, more the acyl
chains are long and saturated, more the phase is liquid-ordered and
more the membrane is thick [29]. The cholesterol is able to order un-
saturated acyl chains of glycerophospholipids, increasing membrane
thickness while maintaining the membrane ﬂuidity [28]. The combi-
nations sphingolipids-cholesterol create membrane domains char-
acterized by an increased membrane thickness and a high lipid packing
and order [36]. An increased PtdCho/PtdEtn ratio is often associated to
a lower membrane ﬂuidity [88].
It is obvious that these membrane physicochemical properties in-
ﬂuence the activity of integral proteins. The transmembrane (TM) part
of the protein, often composed of one or several α-helices, is poor in
polar residues. The length of the hydrophobic core of its TM domain has
to match the hydrophobic thickness of the membrane in order not to
expose non-polar residues to water. A membrane thickening can induce
a conformational modiﬁcation of the TM domain and thereby can in-
activate the protein [89]. The mismatch-induced deformation in the
lipid matrix may also induce an indirect, lipid-mediated attraction be-
tween two proteins [89]. On the other hand, the lack of freedom
mediated by a loss of membrane ﬂuidity can prevent the TM domain
conformational transitions required for the catalytic cycle [90]. Besides
membrane physicochemical properties, the modiﬁcations of the mem-
brane lipid composition can also directly modulate the speciﬁc lipid-
proteins interactions [91].
Several studies have shown that the composition of membrane
phospholipids is inﬂuenced by the fatty acid composition of the diet
[92–94]. A SFA-rich diet will promote a decrease of membrane ﬂuidity.
A carbohydrate-rich diet will also have the same trend since glucose is
readily converted into SFAs via de novo lipogenesis (DNL) in liver and
adipocytes, which can then be distributed throughout the body via li-
poproteins or as free fatty acids [95]. Besides diet, an aberrant lipid
metabolism can also lead to alterations in membrane lipid composition
as seen in some cancer cells [96] or in hepatocytes from obese mice
[97].
A so-called “Western diet” rich both in saturated fat and carbohy-
drates combined with a sedentary lifestyle and genetic risk factors
promote energy imbalance and the accumulation of fat depots.
Nowadays, it is obvious that obesity strongly increases the risk of de-
veloping metabolic disorders like insulin resistance and type 2 diabetes
mellitus (T2DM) [98]. FFAs concentrations are actually increased in the
plasma and insulin-target tissues of obese patients [99]. A decreased
membrane ﬂuidity has been observed in several kinds of cells in pa-
tients with T2DM (red blood cells, leucocytes, platelets, cardiac myo-
cytes, ileal enterocytes,…) [100]. Analysis of membrane lipid compo-
sition also demonstrated an enrichment of lipid species known to make
the membranes less ﬂuid [101–103]. At least two large longitudinal
studies demonstrated a correlation between the SFAs levels in red blood
cells membranes and the susceptibility to develop T2DM [104,105].
Furthermore, several studies have shown that insulin receptor signaling
and GLUT4 transport to the plasma membrane are impaired by a de-
creased membrane ﬂuidity [106–108]. Altogether, these observations
have led researchers to postulate that a loss of membrane ﬂuidity could
contribute to the development of obesity-related insulin resistance and
T2DM [100].
The following paragraphs describe three other kinds of membrane
proteins modulated by membrane lipid alterations, namely the Toll-like
receptor 4 (TLR4), the Na, K-ATPase and sarco(endo)-plasmic Ca-
ATPase and the ER stress transducer, IRE-1 (inositol requiring enzyme
1). The emphasis is put on both underlying physicochemical mechan-
isms and relevance in obesity-linked inﬂammatory and metabolic dis-
orders.
4. TLR4, the case of an innate immunity receptor modulated by
lipid rafts
The Toll-like receptor (TLR) family in humans comprises 10 pa-
thogen recognition receptors (PRR) [109]. The best studied member,
TLR4, has been identiﬁed as the receptor of lipopolysaccharide (LPS,
endotoxin) anchored in the outer membrane of Gram-negative bacteria.
LPS is composed of three parts: the Lipid A, the most conserved part
containing several acyl chains and mediating the pro-inﬂammatory
activity, the central oligosaccharidic core and the terminal O-antigen
composed of a variable polysaccharidic chain [110]. TLR4 is a trans-
membrane protein mainly expressed on myeloid cells, containing 22
leucine-rich repeats (LRRs) in its typical horseshoe-shaped extracellular
domain, 21 amino-acids in its transmembrane helix (TMH) and about
200 amino-acids for its intracellular part characterized by the presence
of the conserved Toll/IL-1 receptor (TIR) domain [111]. TLR4 activa-
tion in response to LPS triggers a pro-inﬂammatory response allowing
the eradication of the bacteria [112]. However, abnormal host response
to LPS can cause a systemic inﬂammatory state called sepsis [112].
Furthermore, TLR4 has been shown to play a role in other pathological
conditions involving endogenous ligands, notably in obesity-linked in-
sulin resistance and T2DM [113,114].
The usually accepted model of TLR4 activation by LPS is the fol-
lowing one [115] (Fig. 4A). The LPS-binding protein (LBP) in the serum
promotes the transfer of LPS monomer to CD14, a myeloid cell speciﬁc
protein that is GPI-anchored in the outer leaﬂet of plasma membrane.
CD14, in turn, shifts the LPS to the hydrophobic pocket of MD2 in the
complex TLR4/MD2. However, one of the acyl chains of the LPS in-
teracts with a neighboring TLR4 molecule allowing the formation of the
“M” shaped dimers of the complex TLR4/MD2. This homodimerization
triggers the recruitment of adaptor proteins through homotypic TIR-TIR
interactions [116]. TIRAP (TIR‐containing adaptor protein) and MyD88
(myeloid diﬀerentiation factor 88) initiate a signaling cascade involving
NF-κB and the MAP kinases and leading to the production of pro-in-
ﬂammatory cytokines such as tumor necrosis factor-α (TNF-α) and in-
terleukin-6 (IL-6) while TRIF (TIR-domain-containing adapter-inducing
interferon-β) and TRAM (TRIF-related adaptor molecule), after TLR4
endocytosis, induce the activation of IRF3 (interferon response factor 3)
and the expression of type 1 interferons (IFN) and IFN-inducible che-
mokines, notably IL-10 and RANTES [116].
CD14 plays a key role in TLR4-mediated signaling as demonstrated
by studies on transgenic and knockout mice developing a hypersensi-
bility or a resistance to septic shock, respectively [117–119]. This co-
receptor not only facilitates the LPS transfer to the complex MD2/TLR4
but also promotes TLR4 internalization [120,121]. Since CD14 is a GPI-
anchored membrane protein, it constitutively accumulates in the outer
leaﬂet of membrane rafts. Studies measuring the ﬂuorescence re-
sonance energy transfer (FRET) between proteins known to be con-
stitutively associated to rafts and other selected proteins demonstrated
that LPS could induce a raft-based molecular platform containing CD14,
TLR4 and other proteins susceptible to participate both to the LPS re-
cognition and downstream events [122]. Interestingly, analyses of
ﬂuorescence recovery after photobleaching (FRAP) showed that the
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lateral mobility of TLR4 in the plasma membrane is decreased after LPS
stimulation suggesting its sequestration in rafts [123]. Lipid raft in-
tegrity is required for LPS signaling as demonstrated by the inhibiting
eﬀect of raft-disrupting drugs [122]. Proteomic analyses performed on
the detergent-resistant membrane (DRM) fraction of macrophages re-
vealed the LPS-induced recruitment of several proteins such as CD14,
CD44, Src family tyrosine kinases, Hsp70, Hsp90, acidic sphingomye-
linase,… [124]. Altogether, these data show that TLR4 activation is
concomitant to its association with other accessory proteins at the site
of CD14-LPS ligation, within the membrane rafts (Fig. 4A) [125].
Since the formation of membrane rafts is mediated by preferential
interactions between cholesterol and sphingolipids, it is not surprising
that the depletion or enrichment of cholesterol in the plasma mem-
branes prevents or promotes, respectively, the TLR4 clustering with
accessory proteins in rafts and the TLR4-dependent pro-inﬂammatory
signaling [122,123,126,127]. The ﬁrst study devoted to the investiga-
tion of FFA eﬀects on TLR4 signaling showed that lauric (C14:0), pal-
mitic (C16:0), and stearic (C18:0) acids could induce cyclooxygenase-2
expression through a TLR4-dependent mechanism in a macrophage cell
line and this SFA-mediated stimulating eﬀect could be inhibited by
PUFA [128]. Later, the same group demonstrated that SFAs could
induce the dimerization of TLR4 as well as its recruitment with eﬀector
molecules to the DRM fraction [129]. Obviously, the next step was to
investigate the mechanism by which SFAs activate TLR4. The hypoth-
esis in favor of a direct interaction between SFAs and the complex
TLR4/MD2 was eliminated [130,131]. Instead, an indirect mechanism
involving the glycoprotein, fetuin A, was proposed to mediate the
binding of SFAs to TLR4. The complex palmitate-fetuin A was shown to
stimulate the pro-inﬂammatory cascade through a TLR4-dependent
pathway [132]. Since then, further studies demonstrated that the fe-
tuin-A plays a key role in the mechanisms linking high fat diet and the
development of a metabolic inﬂammation [133]. However, some ar-
guments suggest that even in the absence of fetuin A, SFAs can induce
TLR4 dimerization without involving the lipid binding pocket of the
complex TLR4/MD2 [134]; ﬁrst, SFAs concentrations required to in-
duce TLR4 dimerization need to be much higher (> 100 µM) than those
of natural ligands (pM) and secondly, the pre-treatment of macrophages
with lauric acid (C14:0) primes LPS-mediated NF-κB activation,
meaning that SFA do not compete with LPS for the binding to the hy-
drophobic pocket of the complex TLR4/MD2. Interestingly, the same
conclusions can be drawn for the SFA-induced dimerization of the TLR2
with TLR1, both receptors that also carry lipid binding pockets for the
Fig. 4. Membrane proteins modulations by the membrane physicochemical properties. (A) Lipid raft-mediated TLR4 activation. The LPS-binding protein (LBP) in the serum promotes the
transfer of LPS monomer to CD14, a myeloid cell speciﬁc protein that is GPI-anchored in membrane rafts. CD14, in turn, shifts the LPS to the hydrophobic pocket of MD2, recruiting the
complex TLR4/MD2 in lipid rafts. One of the acyl chains of the LPS interacts with a neighboring TLR4 molecule allowing the formation of the “M” shaped dimers of the complex TLR4/
MD2. This homodimerization triggers the recruitment of TIRAP (TIR-containing adaptor protein) and MyD88 (myeloid diﬀerentiation factor 88) leading to the production of pro-
inﬂammatory cytokines while others adaptors initiate the signaling pathways allowing the expression of type 1 interferons. (B) The OLE pathway from S. cerevisiae senses and regulates
membrane ﬂuidity. The rotational conﬁgurations of Mga2 and Spt23 control their ubiquitylation and the proteolytic generation of a 90 kDa transcription factor (p90) that induces the
expression of OLE1 in the nucleus. The conserved tryptophan residue (W) in the transmembrane region senses the alteration of lipid packing caused by acyl chains saturation. In a tightly
packed membrane, the tryptophan residue is less adapted to the membrane environment and rotates to point toward the dimer interface. (C) IRE-1 and ER membrane homeostasis.
Unfolded proteins in the ER lumen (1) and ER lipid bilayer stress (2) induce IRE-1 oligomerization and UPR activation. IRE-1 dimerization followed by its auto-phosphorylation and the
unconventional splicing of the XBP1 mRNA by its endoribonuclease activity generates the XBP1(S) transcription factor that activates UPR gene expression. (3) In membranes with highly
packed lipids, a local membrane compression is caused by the IRE-1 amphipathic helix (AH, in pink) located on the ER lumenal side. Upon oligomerization of IRE1, the total area of
membrane compression (blue rectangles) is reduced.
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fatty acyl chains of their natural ligand (acylated lipopeptides) [135].
Since phospholipids in lipid rafts are pre-dominantly acylated by sa-
turated fatty acids, these ones were proposed to mediate the homo-
dimerization of TLR4 or hetero-dimerization of TLR2 and TLR1 by
promoting the formation of lipid rafts and the TLRs recruitment [134].
This hypothesis is reinforced by the observation that ω-3 PUFA are able
both of modifying the lipid composition of lipid rafts and inhibiting
LPS- or lauric acid-induced TLR4 dimerization into lipid raft fractions
[128,136,137].
In vivo, such dietary compounds like cholesterol, SFAs, MUFAs, ω3
and ω9 PUFAs modulate the pro-inﬂammatory activity of TLR4. Indeed,
a diet rich in saturated fat increases susceptibility of mice to sepsis
[138] while ω3 PUFAs have been shown beneﬁcial in protecting hu-
mans and rodents against sepsis [139]. On the other hand, obese pa-
tients display an exacerbated morbidity from sepsis [140]. In addition
to sepsis, TLR4 is known to play a role in the development of obesity-
linked inﬂammation and insulin resistance as demonstrated in TLR4
deﬁcient mice and in subjects with the most common loss-of-function
TLR4 polymorphisms [113,114,133]. SFAs whose levels are sig-
niﬁcantly increased in the plasma and adipose tissue of obese in-
dividuals are among the major endogenous triggers of TLR4 in obesity
[99]. More recently, changes in the landscape of the gut microbiota
related to obesity and commonly associated diseases have been pro-
posed to be at the origin of an increased gut permeability and LPS
leakage leading to increased LPS levels in the blood [141–143]. To-
gether, LPS and SFAs could act synergistically and systemically to in-
duce TLR4 dimerization and activation in membrane rafts and to pro-
mote inﬂammation in obesity.
5. The Na, K-ATPase and sarco(endo)-plasmic Ca-ATPase
regulated by both general and speciﬁc lipid-protein interactions.
Discovered 60 years ago, the Na, K-ATPase is currently considered
as an essential and ubiquitous membrane transport protein whose pri-
mary function is the establishment and maintenance of high K+ and
low Na+ concentrations in the cytoplasm [144]. Such concentrations
are important for various enzymatic functions within the cell. Fur-
thermore, energy stored in the ionic gradients across the plasma
membrane is used for secondary transport of molecules (neuro-
transmitters, metabolites,…) and other ions (H+, Ca2+, Cl−). The ion
gradients also enable rapid signaling by opening of sodium or po-
tassium selective channels in the plasma membrane in response to ex-
tracellular signals.
Minimal functional unit of the Na, K-ATPase is composed of a large
α catalytic subunit and a scaﬀolding β glycoprotein [145]. The Na, K-
ATPase belongs to the P-type ATPase family characterized by the Al-
bers–Post reaction mechanism [146]. This one involves the ATP-de-
pendent cyclic transition of the Na, K-ATPase between two diﬀerent
conformational states, E1 and E2, which binds three Na+ and two K+,
respectively. Diﬀerent α isoforms are expressed in a tissue-speciﬁc
manner [147,148]. The α1 isoform is ubiquitous, the α2 and α3 iso-
forms are expressed in skeletal muscle, neuronal tissue and cardiac
myocytes. The α4 isoform is only expressed in the testis. The various
isoforms fulﬁll speciﬁc conditions required by the diﬀerent cell types to
maintain ionic homeostasis. The overall structure of the Na, K-ATPase is
composed of ten TMHs important for ion binding and three cytosolic
domains, the N-terminal domain mediating ATP binding, the P-domain
carrying phosphorylation sites and the A-domain that confers ATP hy-
drolyzing activity [149,150].
Many organs such as kidneys, brain and testis use the sodium and
potassium gradients for their specialized functions [151]. Mutations in
the genes of the various α isoforms have severe and often neurological
consequences [151].
All α isoforms contain a binding site in their extracellular domain
for cardiotonic steroid (CTS) compounds, such as ouabain and digitoxin
produced by plants [152,153]. The CTS stabilize the Na, K-ATPase in E2
conformation, thereby inhibiting its pump activity [154]. Low levels of
endogenous ouabain can be measured in human plasma and were
proposed to be produced by the adrenal cortex [152,153]. In cardiac
myocytes, CTS induce an increase of intracellular Na+, which leads to
the accumulation of intracellular Ca2+ through functional coupling to
the Na+/Ca2+ exchanger (NCX) stimulating contractility [155]. Since
CTS concentrations much lower than Na, K-ATPase IC50 were re-
cognized a long time ago to stimulate growth-linked pathways, the Na,
K-ATPase is suspected to have functions independent on its pump ac-
tivity [156]. Besides the control of ionic concentrations, it is now well-
accepted that the Na, K-ATPase plays a key role in cellular signal
transduction through both direct interactions with signaling proteins
and its ability to organize speciﬁc membrane microdomains [156].
The Na, K-ATPase pump activity has been known for a long time to
be modulated by the physical properties of the lipid bilayer. These
studies were based on model systems using reconstitution of the Na, K-
ATPase into liposomes of deﬁned lipid composition. The so-called hy-
drophobic matching principle proposes that the hydrophobic core of the
protein transmembrane (TM) domain has to match the hydrophobic
thickness of the membrane to avoid the exposition of non-polar residues
to water [157]. The bilayer thickness increases with both the length of
phospholipids acyl chains and the percentage of cholesterol. Accord-
ingly, the activity of the Na, K-ATPase reconstituted into liposomes is
inﬂuenced by the acyl chains length in a way dependent on the per-
centage of cholesterol [91,158]. The optimum was reached for a smaller
number of C atoms when cholesterol was added, reinforcing the hy-
drophobic matching hypothesis [91,158]. However, in liposomes where
the bilayer thickness is optimal either with or without cholesterol, the
enzymatic activity is strongly boosted by the presence of cholesterol
[91,158]. From that moment, speciﬁc cholesterol-mediated eﬀects were
proposed in addition to its general eﬀects on physicochemical proper-
ties of biological membranes. Later, this hypothesis was conﬁrmed
when speciﬁc cholesterol binding sites were resolved in the crystal
structure of the Na, K-ATPase [159,160]. Thanks to the development of
membrane protein crystallization within the last decade, speciﬁc in-
teractions of the Na, K-ATPase not only with cholesterol but also with
phospholipids were highlighted in three distinct pockets of the TM
domain [91,160]. Biochemical studies were required to address both
the role and precise location of each bound lipid. The eﬀects of phos-
pholipids and cholesterol were determined on the wild type or mutated
recombinant Na, K-ATPase puriﬁed in mixed detergent–lipid–protein
micelles in the absence of a lipid bilayer. These studies indicated that
(1) anionic lipids (optimally 18:0/18:1 PtdSer) and cholesterol bind in
pocket A and are required to stabilize the Na, K-ATPase [91,161,162]
(2) polyunsaturated neutral phospholipids (optimally 18:0/20:4 or
18:0/22:6 PtdCho/PtdEtn) stimulate the Na, K-ATPase activity prob-
ably through the pocket B [91,163,164] (3) saturated PtdCho or
sphingomyelin+ cholesterol inhibit the Na, K-ATPase activity likely
through the pocket C, known also to host cholesterol [91,164]. Very
recently, the team of Karlish, through native mass spectrometry (MS)
and site-directed mutagenesis, identiﬁed the PtdSer and PtdCho/PtdEtn
speciﬁc binding sites and underlying modulation mechanisms: PtdSer
(and cholesterol) bind between αTM 8, 9, 10, and maintain topological
integrity of the labile C terminus of the α subunit (site A) while PtdCho/
PtdEtn bind between αTM2, 4, 6, and 9 and accelerate the rate-limiting
E1P–E2P conformational transition (site B) [165].
Interestingly, a correlation between a decreased Na, K-ATPase ac-
tivity and a higher saturation level of membrane phospholipids in er-
ythrocytes has been already demonstrated in hypertension cases
[166,167]. An alteration of the Na, K-ATPase activity was also observed
in insulin-resistant tissues of obese individuals and proposed as a risk
factor for cardiovascular diseases [168,169].
The sarco/endoplasmic reticulum (SR/ER) Ca2+ ATPase (SERCA),
belonging to the same P-ATPase family, transports calcium ions from
the cytoplasm to the SR/ER and plays a key role in Ca2+ homeostasis
[170]. Diﬀerent SERCA isoforms encoded by three diﬀerent genes are
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diﬀerentially expressed according to the species and tissues [170]. The
crystal structures of skeletal muscle SERCA1a in phospholipid bilayer
have been determined for several conformational states of the reaction
cycle [171]. More recently, the entire ﬁrst layer of phospholipids sur-
rounding the transmembrane helices of Ca2+-ATPase in four diﬀerent
states was resolved [172]. Interestingly, speciﬁc protein-phospholipid
interactions have been shown to enable the reaction cycle. Two classes
of protein residues mediate these interactions: (1) some basic residues
(Arg/Lys) snorkel from within the bilayer, exhibiting their positively
charged side chain to the negative head groups of speciﬁc phospholi-
pidic partners, leading to a local distorsion when the transmembrane
helices move to reach the next conformational state while other basic
residues can interact through a reversible way with diﬀerent phos-
pholipids from above to facilitate the conformational switch, (2) Trp
residues enable the tilt of the entire protein allowing the large per-
pendicular movements of the transmembrane helices during the reac-
tion cycle. Surprisingly, the fatty acyl chain properties such as the
length or the saturation level do not seem to inﬂuence the PtdCho
binding to speciﬁc sites [173]. However, the impact of these mod-
iﬁcations on the pump activity has not been yet investigated. Unlike the
Na, K-ATPase, the absence of speciﬁc cholesterol binding sites in the
SERCA1a crystal structures ﬁts with the very low levels of this sterol in
ER membranes [91]. Both closely related Na, K-ATPase and Ca-ATPase
seem to have adapted to their own lipid environment. Accordingly,
contrary to the Na, K-ATPase, the activity of SERCA1a is not promoted
by cholesterol [91]. SERCA1a was even inhibited when reconstituted in
synthetic vesicles containing PtdCho/PtdEtn in the presence of cho-
lesterol [174].
Some reports demonstrated that an increase of ER membrane lipid
order through cholesterol or saturated PtdCho enrichment could inhibit
the ubiquitous isoform SERCA2b probably through the decrease of its
conformational freedom [90]. Authors suggested that this cholesterol-
mediated SERCA2b inhibition would cause the depletion of ER calcium
stores, that is an event well-known to trigger ER stress and apoptosis of
cholesterol-loaded macrophages in advanced atherosclerotic lesions
[90].
The SERCA inhibition in response to a ER membrane remodeling
was also observed in liver of obese mice [97]. The comparison of both
the proteome and lipidome of hepatic ER between obese and lean mice
revealed an increase in de novo lipogenesis and an alteration in ER lipid
composition. ER lipids were enriched with SFA and MUFA at the ex-
pense of PUFA. In addition, the PtdCho/PtdEtn ratio was increased
from 1.3 in lean mice to 1.97 in obese mice, probably because of the
upregulation of two key genes involved in PtdCho synthesis and PtdEtn
to PtdCho conversion (Choline-phosphate cytidylyltransferase A,
Pcyt1a and Pemt) [97]. The calcium transport activity of microsomes
prepared from livers from these obese mice was impaired compared to
lean mice while the SERCA2b protein level was even slightly higher
[97]. The expression of a short hairpin RNA (shRNA) targeting Pemt
through an adenoviral vector in the liver of obese mice succeeded in
restoring both the normal PtdCho/PtdEtn ratio and calcium transport
activity, suggesting that a too high PtdCho/PtdEtn ratio in ER mem-
brane is an event inhibiting SERCA activity in the liver of obese mice
[97]. Interestingly, all hepatic ER stress markers were also corrected
after Pemt suppression in obese livers, highlighting once again the key
role of SERCA in ER homeostasis. A signiﬁcant reduction in hepatic
steatosis and in both hyperglycaemia and hyperinsulinaemia in obese
mice was also observed after the suppression of hepatic Pemt expression
[97].
6. Homeoviscous adaptation
Poikilothermic organisms that do not control their body tempera-
ture such as bacteria, cyanobacteria, fungi, plants, and ﬁsh increase the
proportion of unsaturated acyl chains in membrane lipids to maintain
ﬂuidity in the cold [175–177]. This mechanism called homeoviscous
adaptation allows the poikilothermic organisms to preserve the mem-
brane ﬂuidity and function over a broad range of temperature
[178–180]. This adaptation is not exclusively focused on lipid acyl
chains. For example, the lipidome of S. cerevisiae cultured at diﬀerent
temperatures shows signiﬁcant diﬀerences in sterol content besides
glycerophospholipids and sphingolipids modiﬁcations [181,182]. In
this section, we will brieﬂy describe the membrane ﬂuidity sensing
mechanisms in bacteria, yeast and nematode that have been deeply
reviewed previously before addressing such systems in mammals
[177–180,183].
The sensing of membrane ﬂuidity in B. subtilis is mediated by DesK,
a membrane dimeric protein with ﬁve transmembrane helices (TMH)
and a cytosolic kinase/phosphatase domain [177]. The membrane
thickening during cooling or saturation of lipid acyl chains is sensed by
DesK that switches from a phosphatase- to a kinase-active state. In these
conditions, Desk autophosphorylates and phosphorylates the tran-
scriptional regulator DesR that, in turn, allows the expression of the des
gene encoding for Δ5-desaturase [179,184,185]. The Δ5-desaturase
catalyzes the introduction of a cis-double bond at the Δ5-position of a
wide range of SFAs [186–188]. The incorporation of newly synthetized
UFAs in membrane phospholipids allows to restore membrane ﬂuidity.
The recovery of initial membrane thickness favors the phosphatase-
active state of DesK that turns oﬀ des transcription through the de-
phosphorylation of DesR [179].
In eukaryotes, the situation becomes more complicated. Indeed,
they are endowed with diﬀerent organelles with a speciﬁc membrane
composition and function. As described above, the plasma membrane is
thicker than ER and Golgi membranes [189]. Due to this great diversity
in membrane biophysical properties, eukaryotic cells had to establish
another membrane surveillance mechanism that does not rely on the
sensing of membrane thickness. Such mechanism was described in S.
cerevisiae that developed a pathway able to sense ﬂuctuations in ER-
membrane lipid packing and to lead to the expression of the single and
essential Δ9-FA desaturase, Ole1, hence the name “OLE pathway” [178]
(Fig. 4B). Two homodimeric transcription factors, Mga2 and Spt23,
embedded in ER membrane via a C-terminal TMH control the expres-
sion of OLE1 [176]. The sensor mechanism of dimeric Mga2 involves
rotational motions of its TMH. Interestingly, a conserved tryptophan
residue seems to mediate the sensing of lipid packing; this residue can
point its bulky lateral chain towards a loosely packed lipid bilayer but
when the membrane environment becomes more densely packed, it has
to “hide” inside the dimer then promoting the TMH rotational motion
(Fig. 4B) [190]. This conformational change makes ubiquitylation sites
accessible on the cytosolic side. The E3 ubiquitin ligase Rsp5 recognizes
these membrane-bound precursors of 120 kDa. Once ubiquitinated and
processed by the proteasome, active transcription factors of 90 kDa are
released to induce the expression of OLE1 in the nucleus [191]. It is
likely that the activation of Spt23 occurs via a similar mechanism due to
the high sequence similarity between Mga2 and Spt23 in the sensory
TMH region (86% sequence identity) [183,190].
Finally, a sensing mechanism of the plasma membrane ﬂuidity was
also identiﬁed in the nematode C. elegans and consists of at least two
proteins, PAQR-2 and IGLR2. C. elegans mutants lacking PAQR-2 or
IGLR-2 have identical phenotypes including cold sensitivity, an excess
of SFAs in membranes and a reduced expression of Δ9-desaturase fat-7
[192]. Moreover, both mutants are glucose intolerant, exhibiting a
strong increase in the proportion of SFAs in phospholipids and a con-
comitant lethal loss of membrane ﬂuidity when they are cultivated in
the presence of glucose [192]. The glucose intolerance in the paqr-2 or
iglr-2 mutants can be overcome by mutations that cause increased FA
desaturation or by treatment with mild detergents, conﬁrming that
glucose cytotoxicity results from an altered membrane ﬂuidity [192]. In
the model proposed by the authors, the formation of the complex
PAQR-2/IGLR2 in plasma membrane could be facilitated by the loss of
membrane ﬂuidity, leading to activation of eﬀectors that promote fatty
acid turnover and desaturation. Such eﬀectors are still unknown while
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SBP-1 and NHR-49, both C. elegans homologs of the mammalian SREBP
and Hepatocyte Nuclear Factor 4 (HNF4)/ Peroxisome proliferator-ac-
tivated receptor alpha (PPARα), respectively, have been proposed to
fulﬁll this function [192–195]. Interestingly, PAQR-2 is the worm
homolog of the human adipokine receptors, AdipoR1 and AdipoR2
[196–198]. In light of these data and since the adiponectin exerts a
well-known diabetes-preventing eﬀect, it is tempting to postulate that
such anti-diabetic eﬀect could be partially mediated through the con-
trol of membrane homeostasis.
7. IRE-1 senses ER lipid bilayer stress through its unusual
amphipathic helix
ER plays a key role in cell homeostasis, mediating both protein
folding and lipid synthesis. When ER is overwhelmed, misfolded pro-
teins accumulate in ER membrane and lumen, creating an ER stress. The
protein folding homeostasis is restored through an adaptative me-
chanism called “unfolded protein response” (UPR) that allows both to
slow translation and upregulate chaperone expression and ER-asso-
ciated degradation machinery (ERAD). In higher eukaryotes, the UPR is
mediated by three main branches, each one characterized by an ER
membrane transducer sensing misfolded proteins in lumen: IRE-1 (in-
ositol requiring enzyme 1), PERK (double-stranded RNA-activated
protein kinase [PKR]-like ER kinase), and ATF6 (activating transcrip-
tion factor 6) [199–202].
IRE-1 is the most conserved sensor of ER stress. It is comprised of a
single transmembrane helix (TMH), an N-terminal ER-lumenal sensor
domain and a C-terminal cytosolic eﬀector domain with serine/threo-
nine kinase and endoribonuclease activities (Fig. 4C). Upon the binding
of unfolded proteins and the dissociation of the chaperone BiP, IRE-1
homodimerizes and goes through trans-autophosphorylation which
promotes the activation of its endoribonuclease (RNase) activity. Its
RNase activity induces the splicing of XBP1 (X-box binding protein-1)
mRNA. The XBP1(S) protein translocates to the nucleus where it binds
to UPR elements (UPREs) that regulate the expression of ERAD ele-
ments, chaperones and genes involved in lipid synthesis [202–204].
The branch IRE-1/XBP1 is a well-characterized lipid synthesis reg-
ulating pathway. Forced XBP1(S) expression increases ER size due to
membrane expansion, concomitant with PtdCho and PtdEtn biosynth-
esis and increased expression of lipid synthesis genes [205–207]. Be-
sides, genetic deletion of Xbp1 gene reduces ER size [208]. The increase
of ER volume is an important mechanism for resolving ER dysfunction
because it helps to rescue luminal protein misfolding independently on
chaperones [209]. Accordingly, misfolded proteins-activated UPR
controls cellular lipid levels and ER size.
Interestingly, it has become obvious that UPR sensors are also
highly inﬂuenced by the properties of the surrounding membranes. In
absence of ER-lumenal domain required for the binding of unfolded
proteins, IRE-1 and PERK are activated by an aberrant membrane en-
vironment such as excess of saturated lipids [210]. Moreover, IRE-1 can
sense diverse abnormalities in ER membrane caused, for example, by
inositol depletion, impaired PtdCho biosynthesis, disrupted sterol
homeostasis and sphingolipid production, as well as by increased levels
of saturated lipids [39,210–215]. It was shown that TMH is essential for
the membrane sensing properties of IRE-1α and PERK but underlying
mechanisms have remained elusive for a long time [210].
However, Halbleib et al. could recently decipher the molecular
mechanism of lipid bilayer stress-mediated IRE-1 activation [203].
Their attention was drawn by the unusual and conserved architecture of
IRE-1 TMH; an amphipathic helix (AH) is adjacent to the TMH on the
ER-lumenal side (Fig. 4C). Using knock-in yeast strains expressing Ire1
wt or Ire1 carrying mutations disrupting the amphipathic character of
its AH, authors could demonstrate that this unusual structure was re-
quired for Ire1 functionality [203]. The TMH region containing the
intact or mutated juxta-membrane AH was reconstituted in diﬀerent
kinds of liposomes; more the lipid packing was dense, more
oligomerization of the wild type peptide was stimulated while the
mutated peptide did not oligomerize whatever the level of lipid
packing. Altogether, these data suggest that Ire1 uses its AH to sense
lipid bilayer stress. Molecular dynamic (MD) simulations of the wt or
mutated sensor peptide allowed them to propose a model for the
membrane-based Ire1 activation mechanism (Fig. 4C). AH with both its
hydrophilic part facing the aqueous environment and its hydrophobic
part entering the lipid bilayer forces the TMH into a highly tilted po-
sition inside the membrane (Fig. 4C). Accordingly, wt sensor peptide
induces a local membrane compression and a disordering of the lipid
acyl chains which are more pronounced in a more ordered and thicker
membrane environment. In this case, Ire1 oligomerization is en-
ergetically more favorable. The mutation inducing a loss of the am-
phipathic character prevents the corresponding residues to insert into
the lipid bilayer and to exert a membrane compression [203]. Inter-
estingly, this sensory mechanism radically diﬀers from the rotational
motions of the Mga2 THM that control the production of unsaturated
lipids via the OLE pathway.
Therefore, besides the initially known property of UPR in main-
taining ER protein homeostasis, the UPR senses and resolves ER lipid
bilayer aberrancies. IRE-1 orchestrates therefore lipid membrane and
protein folding homeostasis providing new comprehensive mechanisms
of the UPR activation and control via interdependent and combined
ways.
Interestingly, both modulations in the ER lipid composition and
UPR activation are observed in morbid obesity [216,217]. Furthermore,
ER stress deeply linked to mitochondrial dysfunction and ROS (reactive
oxygen species) production has been involved in the development of
insulin resistance or beta-cell death in morbid obesity [218–222].
8. Conclusions
A growing number of data indicate that the disruption of membrane
homeostasis can be an event triggering signaling cascades through both
the modulation of membrane receptors, transporters, ionic pumps,
channels or the activation of membrane surveillance systems. Such
membrane remodeling can occur in response to an aberrant metabolism
as seen in obesity. We have addressed these issues by focusing on the
TLR4, the Na, K-ATPase and SERCA and ﬁnally the ER stress sensor,
IRE-1 in order to illustrate diﬀerent modes of membrane sensing that
are relevant in the context of obesity. Obviously, several other mem-
brane receptor systems such as growth regulatory (epithelial growth
factor receptor, EGFR), neurological (serotonin, acetyl choline, opioid
receptors), immunological (CD40 receptor and T-cell receptor) and
rhodopsin-like G protein-coupled receptors are also modulated by
membrane lipids and are the focus of other comprehensive reviews
[45,223,224].
The impact of a membrane remodeling on TLR4 function stems from
the fact that its activation requires its translocation in the plane of
plasma membrane, leading to its association with CD14 and its homo-
dimerization in membrane rafts [122–125]. The involvement of lipid
rafts in the TLR4 activation mechanism partially accounts for its role in
obesity-linked inﬂammation [139]. This kind of raft-based molecular
platform is not without precedent in immune pathways since it has been
also described upon activation of immunoreceptors like the TCR and
BCR [45].
The Na, K-ATPase exempliﬁes a new concept according to which
direct interactions between speciﬁc residues and particular lipids de-
termine both stability and activity of the pump in parallel with indirect
eﬀects of the lipid bilayer [91]. The closely related SERCA embedded in
the more ﬂuid ER membrane seems to be more sensitive to a lipid bi-
layer stress like demonstrated by its inactivation in cholesterol-loaded
macrophages [90] or its inhibition mediated by an increased PtdCho/
PtdEtn ratio in obese mice hepatocytes [97].
Very recently, an IRE-1-mediated mechanism able to sense ER lipid
bilayer stress and to restore ER membrane homeostasis was proposed in
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mammals [203]. Interestingly, an unusual amphipathic helix conserved
among IRE-1 proteins is embedded in the luminal face of the ER
membrane, adjacent to the transmembrane domain and causes a local
membrane compression. The model of IRE-1 activation suggests that
the total area of membrane compression in a more ordered and thicker
membrane is minimized upon oligomerization of IRE-1. Accordingly,
IRE-1 is also capable to detect defects in the lipid composition of ER
membranes, just as it does detect protein folding dysfunctions within
the ER lumen and it solves both the problems at least partially by sti-
mulating lipid synthesis.
Growing evidence indicates that abnormal lipid synthesis is itself
the primary driver of liver ER dysfunction in some human metabolic
and obesity-related pathologies [225,226]. The recent data concerning
IRE-1 deﬁnitively establish a link between its activation and the lipid
bilayer stress and allow to better understand the exacerbating role of ER
membrane remodeling in such metabolic diseases. Hepatocytes upre-
gulate TG synthesis in response to nutrients. The TG synthesis pathway
overlaps with that of membrane glycerophospholipids. Under condi-
tions of excess TG production like in obesity, the synthesis of membrane
glycerophospholipids is also upregulated producing an alteration in the
saturation proﬁle and in the ratio PtdCho/PtdEtn of ER membrane
phospholipids [97,227]. These perturbations in ER membrane lipid
composition not only induce a dysfunction of the SERCA calcium pump
followed by a protein misfolding due to impaired function of calcium-
dependent chaperones but are also directly sensed by IRE-1 creating a
vicious cycle by further increasing lipid synthesis and ER dysfunction
[97,227]. Since the liver plays a central role in the control of circulating
lipids, this hepatic ER disorder contributes to the development of sys-
temic metabolic defects such as hyperglycemia and insulin resistance.
The NLRP3 inﬂammasome activation is another cellular event both
associated to membrane remodeling and relevant in obesity-linked
metabolic disorders. This molecular complex mediates the processing of
the Pro-IL-1β into mature IL-1β and is activated in response to many
danger-associated molecular patterns (DAMPs) [228]. It is well-known
to instigate the obesity-linked inﬂammation and insulin resistance
[229]. We demonstrated its activation in SFAs-treated human macro-
phages as well as in visceral adipose tissue macrophages of metaboli-
cally unhealthy obese [230–233]. Interestingly, SFA-mediated NLRP3
inﬂammasome activation was recently shown to be associated to an
accumulation of saturated PtdCho in macrophages membranes [234].
The sensing mechanism is still under investigation.
In light of these recent data, the previous “membrane-centric view
of T2DM” comes back to the point and opens novel experimental and
therapeutic avenues [100]. Due to the new sophisticated techniques
allowing to study the lipidome and the biophysical properties of bio-
logical membranes, new mechanisms able to sense and restore the
speciﬁc membrane lipid composition of other organelles such as mi-
tochondria will be probably discovered in the next future.
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